U.S. Biomarker Technologies Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Biomarker Technologies Market
- ✓Market Size 2024: USD 29.6 billion
- ✓Market Size 2032: USD 52.5 billion
- ✓CAGR: 7.5%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Coverage Evidence Early: Diagnostics developers should commission MolDX technical assessment dossiers by Q3 2026, before commercial launch. Pre-submission evidence packages cut Medicare coverage delays that frequently exceed twelve months for novel biomarker tests, securing reimbursement at launch.
Biomarker Technologies in the U.S.: Market Overview
The U.S. biomarker technologies market was valued at USD 29.6 billion in 2024 and is forecast to reach USD 52.5 billion by 2032, growing at a CAGR of 7.5%. The market is structured across genomic sequencing, proteomic assays, imaging biomarkers and liquid biopsy platforms, with reference laboratories and academic medical centers serving as the principal purchasers. Federal research funding through the National Institutes of Health has seeded foundational discovery work, while pharmaceutical sponsors provide the private capital that drives commercial scale.
Policy has shaped this structure more than any single commercial force. The 21st Century Cures Act of 2016 directed the Food and Drug Administration to establish the Biomarker Qualification Program, creating a public pathway for biomarkers used in drug development. Government has been dominant in research funding and evidence standards, while the private sector leads assay commercialization, with Thermo Fisher Scientific, Roche Diagnostics and Illumina capturing most platform revenue.
Policy-Driven Growth in U.S. Biomarker Technologies
The first mechanism is the 21st Century Cures Act (Public Law 114-255), which requires the FDA to accept qualified biomarkers as drug development tools through its formal qualification process. Pharmaceutical sponsors use qualified biomarkers to enrich trial populations, which translates into recurring demand for companion diagnostics and validated assays. Each qualified biomarker converts a one-time research purchase into sustained commercial volume across multi-year clinical trial programs.
The second mechanism is the Precision Medicine Initiative, funded through the Cures Act with USD 4 billion authorized and delivered by the National Institutes of Health as the All of Us Research Program. Its genomic datasets drive sequencing and data-analysis procurement across participating institutions. The third mechanism is the Clinical Laboratory Fee Schedule administered by the Centers for Medicare and Medicaid Services, where reimbursement levels determine whether laboratories adopt new biomarker assays at scale.
Regulatory Barriers and Compliance Costs in U.S. Biomarkers
Clinical Laboratory Improvement Amendments certification, administered by the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendments of 1988, is the first barrier for any laboratory offering biomarker tests. Certification requires proficiency testing, personnel qualifications and quality-control documentation, with application fees and inspection costs running into tens of thousands of dollars per site. Laboratories operating across multiple states must also satisfy state licensing rules, including New York State's Clinical Laboratory Evaluation Program.
The Protecting Access to Medicare Act of 2014 requires CMS to reset Clinical Laboratory Fee Schedule rates using private payer market data collected every three years. Repeated congressional delays to scheduled rate cuts have created pricing uncertainty for test providers. The FDA's laboratory-developed test rule, finalized in 2024, was vacated by a federal court in March 2025, leaving oversight of many biomarker tests fragmented, so developers must budget for both FDA premarket review and CLIA compliance.
Policy-Created Opportunities in U.S. Biomarker Technologies
The Transitional Coverage for Emerging Technologies pathway, finalized by CMS in 2024, creates a Medicare coverage route for breakthrough devices, capped at five technologies annually. Biomarker developers holding FDA Breakthrough Device designation can obtain provisional coverage with evidence development, shortening the revenue lag that has historically deterred early-stage investment. Developers that align trial design with this pathway gain early reimbursement certainty.
The DOJ bulk sensitive data rule, effective April 2025, restricts transfers of U.S. genomic data to countries of concern, creating demand for domestic secure sequencing and data-processing capacity. Laboratories capable of onshore genomic analysis, particularly those contracting with NIH-funded programs, will capture procurement that previously flowed offshore. This shift favors established U.S. reference laboratories and platform vendors with domestic manufacturing footprints.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 29.6 billion |
| Market Size 2032 | USD 52.5 billion |
| Growth Rate (CAGR) | 7.5% |
| Most Critical Decision Factor | Medicare coverage and reimbursement decisions |
| Largest Region | Northeast (Massachusetts, New York, New Jersey) |
| Competitive Structure | Concentrated in platforms, fragmented in assays |
Leading Market Participants
- Thermo Fisher Scientific
- Illumina
- Roche Diagnostics
- Agilent Technologies
- Qiagen
- Guardant Health
- Natera
- Exact Sciences
- Myriad Genetics
- Danaher
Regulatory and Policy Environment
The primary legislation governing this market is the Federal Food, Drug, and Cosmetic Act, enforced by the Food and Drug Administration for premarket review of companion diagnostics and in vitro diagnostic devices. The Clinical Laboratory Improvement Amendments of 1988 place laboratory-developed tests under CMS oversight, requiring certification, proficiency testing and quality-control documentation. Coverage decisions run through the Medicare Administrative Contractor MolDX program, operated by Palmetto GBA, which evaluates analytical and clinical validity before payment is authorized.
Upcoming changes will shape compliance cost structures. PAMA reporting cycles require private payer rate submissions in 2026 for fee schedule rates effective in 2027, which will recalibrate pricing for multi-gene panels. Compared with regional peers, the U.S. framework lacks the unified premarket certification that the European Union's In Vitro Diagnostic Regulation (EU) 2017/746 imposes through notified bodies, whose transition periods run to 2027 and 2029. This absence leaves U.S. laboratory-developed tests governed mainly by CLIA rather than a device-style premarket standard.
Long-Term Policy Outlook for U.S. Biomarker Technologies
Congress will need to resolve the regulatory status of laboratory-developed tests before 2028, either through legislation modeled on the VALID Act or through a CMS-led evidence framework. Each path will impose different premarket obligations on assay developers, and the choice will determine whether smaller diagnostics firms can sustain multi-biomarker programs. The 2027 PAMA rate cycle will similarly redistribute reimbursement toward validated, clinically useful panels.
By 2032, policy will channel more demand toward domestic genomic infrastructure. Continued enforcement of the DOJ bulk sensitive data rule and expansion of TCET-eligible breakthrough designations will favor U.S.-based sequencing platforms and reference laboratories. Companies that build compliant data governance and coverage evidence into their development programs now will hold the commercial advantage when these frameworks mature.
Frequently Asked Questions
Market Segmentation
- Next-Generation Sequencing
- Mass Spectrometry Proteomics
- Liquid Biopsy
- Multiplex Immunoassays
- Digital Pathology Imaging
- Companion Diagnostics
- Drug Development
- Disease Screening
- Precision Oncology
- Reference Laboratories
- Hospitals and Health Systems
- Pharmaceutical and Biotech Companies
- Academic and Research Institutes
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.